Navigation Links
Encision Reports First Quarter Fiscal Year 2014 Results

BOULDER, Colo., July 31, 2013 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that  prevents stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2014 first quarter ended June 30, 2013.

The Company posted quarterly product revenue of $2.619 million and quarterly service revenue of $63 thousand for a quarterly net loss of $241 thousand, or $(0.03) per share. These results compare to product revenue of $2.805 million and service revenue of $296 thousand for net income of $10 thousand, or $0.00 per share, in the year-ago quarter. Product revenue for the current quarter included $60 thousand of revenue from the distribution of Virtual Ports Ltd. ("Virtual Ports") products, which began in the current quarter. Gross margin on product revenue was 58 percent compared to 57 percent in the year-ago quarter. Interest and other expense, net, included $61 thousand for the medical device excise tax that started January 1, 2013.

"As with our fourth quarter of fiscal year 2013, which ended March 31, 2013, our product revenue decreased for our first quarter versus last year's first quarter," said Fred Perner, President and CEO. "As previously announced, in April and May, we made material expense reductions across all departments within our Company, in order to align expenses with revenues. On an annualized basis, the expense reductions exceeded $1.5 million and included a significant reduction of our workforce. We expect that our operating expenses will realize those expense reductions starting at the beginning of our second quarter that ends September 30, 2013.  The key for us is to get revenues back on track, and we continue to take definitive steps to do so. During our first quarter, we announced an agreement with Virtual Ports for exclusive distribution rights to their laparoscopic organ retraction products in the United States.  Additionally, we continue to pursue our hand-activation strategy with recent product introductions that should improve our penetration of our AEM® Technology.  We have reported that 116,000 procedures used AEM Technology last year and, for our first quarter, we are reporting that 27,000 procedures used AEM Technology, based upon usage of our disposable cords. Importantly, we continue to focus on larger system conversions.  Our ability to convert these systems will play a large role in improving our performance for the remainder of the year." 

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2013 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600,

 Encision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited)June 30, 2013March 31, 2013ASSETSCash and cash equivalents$
26Accounts receivable, net1,018986Inventories, net2,9202,929Prepaid expenses18366Total current assets4,2154,107Equipment, net1,7961,629Patents, net244238Other assets109Total assets$ 6,265$ 5,983LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$   442$ 824Accrued compensation316319Other accrued liabilities443446Lease payable – short term47––Line of credit725––Total current liabilities1,9731,589Lease payable – long term122––Total liabilities2,0951,589Common stock and additional paid-in capital21,58621,570Accumulated (deficit)(17,416)(17,176)Total shareholders' equity4,1704,394Total liabilities and shareholders' equity$ 6,265$  5,983 Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedJune 30, 2013June 30, 2012Net revenue:Product$ 2,619$ 2,805Service63296Total revenue2,6823,101Cost of revenue:Product1,1041,204Service50149Total cost of revenue1,1541,353Gross profit1,5281,748Operating expenses:Sales and marketing951866General and administrative353528Research and development388343Total operating expenses1,6921,737Operating income (loss)(164)11Interest and other expense, net(77)(1)Income (loss) before provision for income taxes(241)10Provision for income taxes––––Net income (loss)$  (241)$Net income (loss) per share—basic and diluted$ (0.03)$  0.00Basic weighted average number of shares8,2108,168Diluted weighted average number of shares8,2108,178

SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision to Release First Quarter 2013 Results on July 31, 2013
2. Encision Reports Fourth Quarter and Fiscal Year 2013 Results
3. Encision Inc. and Virtual Ports Ltd. Announce Exclusive Distribution Agreement for Laparoscopic Surgery Devices
4. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
5. Encision Reports Second Quarter of Fiscal Year 2013 Results
6. Encision Reports First Quarter of Fiscal Year 2013 Results
7. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
8. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
9. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
11. Luminex Corporation Reports Second Quarter 2013 Results
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... Lake, IL (PRWEB) , ... November 25, 2015 , ... ... to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and ... case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... , ... November 25, 2015 , ... In an ongoing ... Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its ... surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 at ...
Breaking Medicine News(10 mins):